AMPH Amphastar P

$26.58

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Amphastar P

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Website: https://www.amphastar.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1297184
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA, US
Valuation
Market Cap
$1.11B
P/E Ratio
7.63
PEG Ratio
2.77
Price to Book
1.51
Performance
EPS
$3.06
Dividend Yield
—
Profit Margin
21.80%
ROE
23.30%
Technicals
50D MA
$28.31
200D MA
$39.69
52W High
$53.95
52W Low
$22.64
Fundamentals
Shares Outstanding
48M
Target Price
$39.00
Beta
0.79

AMPH EPS Estimates vs Actual

● Estimated
● Actual

AMPH News & Sentiment

Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Sep 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Sep 15, 2025 • Zacks Commentary SOMEWHAT-BULLISH
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Sep 02, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Sep 02, 2025 • Zacks Commentary NEUTRAL
Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?
Investors need to pay close attention to AMPH stock based on the movements in the options market lately.
Aug 12, 2025 • Benzinga NEUTRAL
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Sentiment Snapshot

Average Sentiment Score:

0.096
50 articles with scored sentiment

Overall Sentiment:

Neutral

AMPH Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Post market)
-0.02 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.94
  • Whisper: —
  • Surprise %: -1.9%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.96
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: -4.0%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.17 Surprise
  • Reported EPS: $0.94
  • Estimate: $0.77
  • Whisper: —
  • Surprise %: 22.1%
May 10, 2024
Mar 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $1.04
  • Estimate: $0.96
  • Whisper: —
  • Surprise %: 8.3%
Feb 29, 2024
Dec 31, 2023 (Post market)
-0.05 Surprise
  • Reported EPS: $0.88
  • Estimate: $0.93
  • Whisper: —
  • Surprise %: -5.4%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.46 Surprise
  • Reported EPS: $1.15
  • Estimate: $0.69
  • Whisper: —
  • Surprise %: 66.7%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.65
  • Estimate: $0.56
  • Whisper: —
  • Surprise %: 16.1%
May 09, 2023
Mar 31, 2023 (Post market)
0.14 Surprise
  • Reported EPS: $0.62
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: 29.2%
Feb 28, 2023
Dec 31, 2022 (Post market)
0.32 Surprise
  • Reported EPS: $0.73
  • Estimate: $0.41
  • Whisper: —
  • Surprise %: 78.0%

Financials